Loading...

MGRX MANGOCEUTICALS INC Capital Structure Changes 8-K Filing

MNGC

MGRX

MANGOCEUTICALS INC

(MGRX)

2025 8-K

Summary

Summary

Partnership Announcement

Lease and Separation

Equity Grant Report

Private Placement Sale

Asset Acquisitions

Convertible Notes

Equity Offerings

Equity Offerings

Equity Offerings

Management Changes

Debt-Equity Swaps

Asset Acquisitions

Securities Agreement

Equity Conversions

Equity Conversion

Equity Conversion

Distribution Agreement

Stock Amendments

Consulting Agreement

Patent Purchase

Avian Flu Treatment

Agreements Overview

Debt Conversion

Securities Agreement

Securities Agreement

Patent Acquisition

Service Agreement

Management Change

Nasdaq Compliance

Equity Sales Agreement

Promissory Note Issued

Public Claims Response

Stock Split Announcement

Equity Issuance

Stock Sale Update

Financial Results

Distribution Agreement

Agreement with Investor

Annual Meeting of Stockholders

Equity Compensation Awards

Patent Purchase Agreement

Equity Investment

Equity Incentive Plan Amend...

Compliance Extension Grante...

Public Offering

Underwriting Agreement

Marketing Agreement with Ma...

Results of Operations and F...

Appointment of CFO

Agreement with Epiq Scripts...

Unregistered Sales of Equit...

Appointment of COO

External Links:

On July 3, 2025, Mango Pharmaceuticals, Inc. filed a designation for its new 6% Series B Convertible Cumulative Preferred Stock, allowing for 1,000,000 shares with a $10 value per share, providing quarterly dividends starting September 30, 2025.

AI Assistant

MANGOCEUTICALS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.